Online inquiry

IVTScrip™ mRNA-Human APH1B, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WK24908MR)

This product GTTS-WK24908MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the APH1B protein. This product can be used in Ciliated epithelial cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_001145646.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 83464
UniProt ID Q8WW43
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human APH1B, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WK24908MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK25604MR IVTScrip™ mRNA-Human ARHGDIA, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARHGDIA
GTTS-WK7584MR IVTScrip™ mRNA-Human ABTB1, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABTB1
GTTS-WK16818MR IVTScrip™ mRNA-Human AGTRAP, (Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AGTRAP
GTTS-WK10488MR IVTScrip™ mRNA-Human AGAP2, (Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AGAP2
GTTS-WK16441MR IVTScrip™ mRNA-Human ANKUB1, (Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ANKUB1
GTTS-WK11340MR IVTScrip™ mRNA-Human ADGRF5, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ADGRF5
GTTS-WK27379MR IVTScrip™ mRNA-Human ARGLU1, (Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ARGLU1
GTTS-WK20836MR IVTScrip™ mRNA-Human alpha-Sarcoglycan, (Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA alpha-Sarcoglycan
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW